KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Goodwill & Intangibles (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Goodwill & Intangibles data on record, last reported at $1.1 billion in Q3 2025.

  • For Q3 2025, Goodwill & Intangibles fell 43.32% year-over-year to $1.1 billion; the TTM value through Sep 2025 reached $1.1 billion, down 43.32%, while the annual FY2024 figure was $1.1 billion, 43.57% down from the prior year.
  • Goodwill & Intangibles reached $1.1 billion in Q3 2025 per VRTX's latest filing, roughly flat from $1.1 billion in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $1.9 billion in Q4 2023 and bottomed at $603.6 million in Q3 2022.
  • Average Goodwill & Intangibles over 5 years is $1.5 billion, with a median of $1.4 billion recorded in 2021.
  • Peak YoY movement for Goodwill & Intangibles: crashed 56.95% in 2022, then soared 180.25% in 2023.
  • A 5-year view of Goodwill & Intangibles shows it stood at $1.4 billion in 2021, then rose by 20.64% to $1.7 billion in 2022, then grew by 13.97% to $1.9 billion in 2023, then crashed by 43.57% to $1.1 billion in 2024, then changed by 0.0% to $1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Goodwill & Intangibles were $1.1 billion in Q3 2025, $1.1 billion in Q2 2025, and $1.1 billion in Q4 2024.